Advocacy intelligence hub — real-time data for patient organizations
City of Hope Medical Center — PHASE2
Sheba Medical Center — PHASE1, PHASE2
American University of Beirut Medical Center — PHASE2
Abramson Cancer Center at Penn Medicine — PHASE1
International Extranodal Lymphoma Study Group (IELSG)
Sun Yat-sen University — PHASE1, PHASE2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences — NA
Tianjin Medical University Cancer Institute and Hospital — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance5
Zynlonta
(loncastuximab tesirine-lpyl)Orphan drugADC Therapeutics SA
12.1 Mechanism of Action Loncastuximab tesirine-lpyl is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal IgG1 kappa antibody component ...
MONJUVI
(tafasitamab-cxix)Orphan drugIncyte Corporation
12.1 Mechanism of Action Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and matur...
Rituxan
(rituximab)Orphan drugstandardGenentech, Inc.
Endoglycosidase [EPC]
12.1 Mechanism of Action Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. ...
Rituxan SC
(rituximab and recombinant human hyaluronidase)Orphan drugstandardGenentech, Inc.
Jason Westin, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Prof. Dr. Michael Schmitt
University Hospital Heidelberg, Department V
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Yizhuo Zhang
Sun Yat-Sen University Cancer Center
Prof. Dr. Andreas Kulozik
University Hospital Heidelberg, University Medical Center for Children and Adolescents
Paolo Caimi, MD, M.D
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
📍 CLEVELAND, OH